## **Core Concept**
The question pertains to the cardiac safety profiles of various drugs, particularly those used in the management of diabetes or obesity. The focus is on the association of these drugs with cardiac mortality.

## **Why the Correct Answer is Right**
The correct answer, , is associated with the highest cardiac mortality due to its mechanism of action. It was withdrawn from the market in several countries due to concerns over increased risk of heart failure and cardiac mortality. This drug class works by inhibiting the reabsorption of glucose in the kidneys, but its impact on cardiac function can be detrimental, particularly in patients with pre-existing heart conditions.

## **Why Each Wrong Option is Incorrect**
* **Option A:** is not commonly associated with increased cardiac mortality compared to . Its primary concern is related to gastrointestinal side effects.
* **Option B:** has a more favorable cardiac safety profile compared to . It is often used in patients with heart failure.
* **Option D:** does not have a significant association with cardiac mortality that surpasses .

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that certain antidiabetic drugs have been scrutinized for their potential to increase cardiovascular risk. The FDA requires that new antidiabetic drugs demonstrate cardiovascular safety. This has led to a reevaluation of the cardiovascular safety profiles of many drugs used in diabetes management.

## **Correct Answer:** .